erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Definition

  • Inability to attain & maintain an erection enough to have satisfactory sexual performance for at least 3 months

Etiology

  • Increasing evidence have shown that erectile dysfunction can be an early manifestation of coronary artery & peripheral vascular disease

Signs and Symptoms

  • Complete loss of penile rigidity is uncommon
  • A patient may complain of partial erection that could not attain vaginal penetration
  • Initial penile erections can penetrate but early detumescence occurs without ejaculation

Risk Factors

  • Erectile dysfunction has common risk factors as w/ cardiovascular diseases
  • Studies have shown that erectile dysfunction has been associated w/ lower urinary tract symptoms, benign prostatic hyperplasia, & sexual dysfunction regardless of age & other comorbidities & various lifestyle factors
Comorbidities & other risk factors that may contribute to erectile dysfunction:
Arteriogenic
  • Diabetes mellitus
  • Hypertension
  • Cardiovascular disease
  • Hyperlipidemia & the metabolic syndrome
  • Heavy smoking
  • Peripheral vascular disorders
  • Recreational drug abuse
Neurogenic
  • Alcohol abuse
  • Trauma
  • Spinal cord injury
Endocrine
  • Diabetes mellitus
  • Hypogonadism/testosterone deficiency
  • Hyperprolactinemia
  • Hyper- & hypothyroidism
Psychiatric & Psychogenic
  • Depression
  • Anxiety disorders
  • Relationship issues
  • Stress
  • Performance anxiety
  • Loss of attraction
Drugs
  • Antihypertensives (beta-blockers, Spironolactone, Methyldopa, thiazide diuretics)
  • Narcotics
  • Cimetidine
  • Antidepressants
  • Tranquillizers
  • Others
Penile Disorders
  • Peyronie’s disease
  • Severe phimosis
Others
  • Obesity
  • Pelvic radiation therapy
  • Sedentary lifestyle
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.